Advertisement
U.S. markets open in 1 hour 28 minutes
  • S&P Futures

    5,230.00
    -13.25 (-0.25%)
     
  • Dow Futures

    38,672.00
    -60.00 (-0.15%)
     
  • Nasdaq Futures

    18,417.25
    -67.75 (-0.37%)
     
  • Russell 2000 Futures

    2,053.90
    -4.00 (-0.19%)
     
  • Crude Oil

    86.16
    +1.14 (+1.34%)
     
  • Gold

    2,412.20
    +39.50 (+1.66%)
     
  • Silver

    29.14
    +0.89 (+3.13%)
     
  • EUR/USD

    1.0654
    -0.0077 (-0.71%)
     
  • 10-Yr Bond

    4.5760
    0.0000 (0.00%)
     
  • Vix

    15.27
    +0.36 (+2.41%)
     
  • GBP/USD

    1.2471
    -0.0084 (-0.67%)
     
  • USD/JPY

    153.1760
    -0.0270 (-0.02%)
     
  • Bitcoin USD

    70,897.02
    +905.92 (+1.29%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    8,030.21
    +106.41 (+1.34%)
     
  • Nikkei 225

    39,523.55
    +80.92 (+0.21%)
     

Acadia Pharmaceuticals to Participate in TD Cowen’s 44th Annual Health Care Conference on March 6, 2024

SAN DIEGO, February 29, 2024--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in TD Cowen’s 44th Annual Health Care Conference on Wednesday, March 6, 2024, at 11:10 a.m. Eastern Time.

A live webcast of Acadia’s presentation will be accessible on the company’s website, Acadia.com, under the investors section and an archived recording will be available on the website for approximately one month following the presentation.

About Acadia Pharmaceuticals

Acadia is advancing breakthroughs in neuroscience to elevate life. For 30 years we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only FDA-approved drug to treat hallucinations and delusions associated with Parkinson’s disease psychosis and the first and only FDA-approved drug for the treatment of Rett syndrome. Our clinical-stage development efforts are focused on treating the negative symptoms of schizophrenia, Prader-Willi syndrome, Alzheimer’s disease psychosis and multiple other programs targeting neuropsychiatric symptoms in central nervous system disorders. For more information, visit us at Acadia.com and follow us on LinkedIn and Twitter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240229248127/en/

Contacts

Media Contact:
Acadia Pharmaceuticals Inc.
Deb Kazenelson
(818) 395-3043
media@acadia-pharm.com

Investor Contact:
Acadia Pharmaceuticals Inc.
Al Kildani
(858) 261-2872
ir@acadia-pharm.com

Acadia Pharmaceuticals Inc.
Jessica Tieszen
(858) 261-2950
ir@acadia-pharm.com

Advertisement